Stockreport

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook [Yahoo! Finance]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF Net Loss: $37 million or $0.18 per share for Q3 2024. R&D Expense: $35 million for Q3 2024; full year expected between $121-130 million. G&A Expense: $19 million fo [Read more]